Welcome to our dedicated page for MDCX news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on MDCX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MDCX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MDCX's position in the market.
Medicus Pharma (NASDAQ: MDCX) announced the closing of its US$4.0M initial public offering in the United States, consisting of 970,000 units at US$4.125 per unit. Each unit includes one common share and one warrant with a US$4.64 exercise price, expiring in 5 years. The company's shares and warrants began trading on Nasdaq under 'MDCX' and 'MDCXW'. The proceeds will fund Phase 2 clinical trials for basal cell carcinoma treatment using their doxorubicin microarray needle skinpatch, with potential expansion to other non-melanoma skin diseases. The underwriter exercised an overallotment option for 145,500 additional warrants.
